Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Crohn's disease Age: Adult |
Dose: Intravenous infusion – 5 mg/kg Frequency: initially, repeated at 2 weeks after 1st infusion Note: Administer over at least 2 hours. No further doses should be given if there is no response after 2 doses. |
|
Indication: Crohn's disease Age: Adult Condition: Responders (Maintenance) |
Dose: Intravenous infusion – 5 mg/kg Frequency: at 6 weeks after initial dose then every 8 weeks thereafter Note: May be re-administered within 16 weeks after last infusion if signs/symptoms recur. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Crohn's disease Age: 6-17 yr |
Dose: Intravenous – 5 mg/kg Frequency: repeated at 2 weeks and 6 weeks after 1st infusion then 8 weekly thereafter Note: infusion over at least 2 hours |
|
Indication: Ulcerative colitis Age: 6-17 yr |
Dose: Intravenous – 5 mg/kg Frequency: repeated at 2 weeks and 6 weeks after 1st infusion then 8 weekly thereafter Note: infusion over 2 hours |
Administration
- Given as IV infusion
- Must be administered by healthcare professionals
Side Effect
- Upper respiratory tract infection (URTI)
- Sinusitis
- Pharyngitis
- Infusion-related reactions
- Headache
- Abdominal pain
- Viral infection
- Bronchitis
- Urinary Tract Infection (UTI)
- Abscess
- Skin infection
- Moniliasis
- Anemia
- Leukopenia
- Neutropenia
- Thrombocytopenia
- Lymphadenopathy
- Depression
- Insomnia
- Anxiety
- Dizziness
- Vertigo
- Paresthesia
- Hypoesthesia
- Flushing
- Hot flush
- Hypertension
- Hypotension
- Tachycardia
- Palpitations
- Dyspnea
- Cough
- Nosebleed
- Diarrhea
- Nausea
- Vomiting
- Dyspepsia
- Gastroesophageal reflux
- Constipation
- Elevated ALT
- Elevated AST
- Rash
- Pruritus
- Urticaria
- Dry skin
- Hyperhidrosis
- Arthralgia
- Myalgia
- Back pain
- Fatigue
- Fever
- Pain
- Chest pain
- Edema
- Chills
- Tuberculosis
- Sepsis
- Invasive fungal infections
- Lymphoma
- Hepatosplenic T-cell lymphoma
- Skin cancer
- Hepatitis B reactivation
- Hepatotoxicity
- Heart failure
- Myocardial infarction
- Stroke
- Seizures
- Optic neuritis
- Demyelinating disease
- Lupus-like syndrome
- Psoriasis
- Anaphylaxis
- Serum sickness
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Anakinra, abatacept
|
Increased risk of serious infection and neutropenia
|
|
Live vaccines
|
Risk of clinical infections, including disseminated infections
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Active Tuberculosis
|
Risk of TB worsening
|
|
Severe Heart Failure
|
Risk of cardiac complications
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Infliximab must be refrigerated at 2ºC to 8ºC. Do not use Infliximab beyond the expiration date (Exp) located on the carton and the vial. This product contains no preservative.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.